Table 1.
Characteristics of 474 patients with BCLC-A/B HCC beyond the Milan criteria receiving SR or TACE
| Variables | SR (n = 247) | TACE (n = 227) | p value |
|---|---|---|---|
| Age, years | 64 (55–75) | 68 (58–75) | 0.004 |
| Sex | |||
| Male | 200 (81) | 161 (71) | 0.010 |
| Female | 47 (19) | 66 (29) | |
| FIB-4 index | 2.17 (1.50–3.24) | 3.98 (2.29–6.85) | <0.001 |
| ALBI score | −3.01 (–3.22––2.79) | −2.89 (–2.49––1.98) | <0.001 |
| AFP, ng/mL | 20.9 (4.1–526.5) | 40.8 (9.1–373.2) | 0.030 |
| HBV positive | 136 (55) | 112 (49) | 0.213 |
| HCV positive | 46 (19) | 81 (36) | <0.001 |
| Cirrhosis | 99 (40) | 166 (73) | <0.001 |
| Seven-eleven criteria | |||
| Low (<7) | 76 (31) | 73 (32) | 0.062 |
| Intermediate (7-11) | 117 (47) | 86 (38) | |
| High (>11) | 54 (22) | 68 (30) | |
| Tumor number | |||
| 1 | 186 (75) | 59 (26) | <0.001 |
| 2 or 3 | 53 (22) | 115 (51) | |
| >3 | 8 (3) | 53 (23) | |
| Maximum tumor size, cm | 7.0 (5.6–9.8) | 5.6 (3.7–8.9) | <0.001 |
| Follow-up duration, years | 3.9 (2.2–5.2) | 2.1 (1.0–4.1) | <0.001 |
| Death | 76 (31) | 129 (57) | <0.001 |
Data are expressed as median (interquartile range) or number (percentage). BCLC, Barcelona Clinic Liver Cancer classification; HCC, hepatocellular carcinoma; SR, surgical resection; TACE, transarterial chemoembolization; FIB-4 index, fibrosis-4 index; ALBI score, albumin-bilirubin score; AFP, a-fetoprotein; HBV, hepatitis B virus; HCV, hepatitis C virus.